Health Experts Push To Centre Health In Climate Action At World Health Summit 29/10/2019 Elaine Ruth Fletcher Berlin, Germany (29 October 2019) – Experts called on policy-makers to put human health and wellbeing at the centre of climate action decisions at the World Health Summit, which entered its third and final day Tuesday. “There is a need for urgent action to reduce greenhouse emissions to protect health, because we have less than […] Continue reading -> WHO Launches Digital Health Action Plan To Guide Expert Group’s Work 25/10/2019 Grace Ren The World Health Organization has launched a plan to accelerate the use of digital technologies to meet global public health needs, following the first-ever meeting of a WHO Technical Advisory Group on digital health. “All governments are facing increasing demands to provide health services to their citizens, and many digital technologies offer solutions to help meet […] Continue reading -> Drug Pricing Transparency To Be Discussed At World Trade Organization 17/10/2019 Grace Ren A request by South Africa to the World Trade Organization (WTO) TRIPS Council to “address the transparency of R&D costs and pricing of medicines and health technologies” is expected to be reviewed Friday, 18 October 2019 as the TRIPS Council meets this week for its third session this year. The TRIPS Council, the administrative body […] Continue reading -> Fueling An Unhealthy Future – Report Sheds New Light On Health Costs of Fossil Fuel Subsidies 26/09/2019 Elaine Ruth Fletcher NEW YORK CITY – Globally, governments are spending nearly $US 300 billion in price supports and other pre-tax subsidies for fossil fuels – which are costing national governments a whopping $US 2.7 trillion in health costs from air pollution-related mortality, disease and lost productivity—not to mention fueling climate change. As just one stunning example of […] Continue reading -> DR Congo Health Minister Resigns After President Takes Control Of Ebola Emergency 22/07/2019 Editorial team The Democratic Republic of the Congo’s Health Minister, Oly Iluga, resigned Monday, following his removal Saturday as the head of the country’s Ebola response – after the country’s President Felix Tshisekedi placed management of the crisis under direct presidential supervision. “As a result of your decision to place the response to the Ebola outbreak under […] Continue reading -> Drug R&D, Sexual & Reproductive Health Scrutinised In Draft UHC Declaration 19/07/2019 David Branigan Disclosure of costs for drug research and development (R&D) and “alternative financing mechanisms” for new health products remain outstanding points to be resolved by countries in finalising a draft United Nations General Assembly political declaration on universal health coverage (UHC). A final draft of the declaration had been expected this week, but as of Friday […] Continue reading -> WHO is establishing technical advisory group and roster of experts on digital health 10/05/2019 Editorial team [WHO News Release] WHO is establishing a global multi-disciplinary technical group to advise us on issues related to digital health. Continue reading -> Drug Price Transparency: 10 Countries Back World Health Assembly Resolution 30/04/2019 Elaine Ruth Fletcher Ten countries, including five European Union (EU) member states, have now lined up in support of a landmark resolution to increase transparency of drug prices globally, which is expected to be a key focus of deliberations by WHO member states as they convene for the 72nd World Health Assembly (WHA), May 20-28 in Geneva. Image […] Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Launches Digital Health Action Plan To Guide Expert Group’s Work 25/10/2019 Grace Ren The World Health Organization has launched a plan to accelerate the use of digital technologies to meet global public health needs, following the first-ever meeting of a WHO Technical Advisory Group on digital health. “All governments are facing increasing demands to provide health services to their citizens, and many digital technologies offer solutions to help meet […] Continue reading -> Drug Pricing Transparency To Be Discussed At World Trade Organization 17/10/2019 Grace Ren A request by South Africa to the World Trade Organization (WTO) TRIPS Council to “address the transparency of R&D costs and pricing of medicines and health technologies” is expected to be reviewed Friday, 18 October 2019 as the TRIPS Council meets this week for its third session this year. The TRIPS Council, the administrative body […] Continue reading -> Fueling An Unhealthy Future – Report Sheds New Light On Health Costs of Fossil Fuel Subsidies 26/09/2019 Elaine Ruth Fletcher NEW YORK CITY – Globally, governments are spending nearly $US 300 billion in price supports and other pre-tax subsidies for fossil fuels – which are costing national governments a whopping $US 2.7 trillion in health costs from air pollution-related mortality, disease and lost productivity—not to mention fueling climate change. As just one stunning example of […] Continue reading -> DR Congo Health Minister Resigns After President Takes Control Of Ebola Emergency 22/07/2019 Editorial team The Democratic Republic of the Congo’s Health Minister, Oly Iluga, resigned Monday, following his removal Saturday as the head of the country’s Ebola response – after the country’s President Felix Tshisekedi placed management of the crisis under direct presidential supervision. “As a result of your decision to place the response to the Ebola outbreak under […] Continue reading -> Drug R&D, Sexual & Reproductive Health Scrutinised In Draft UHC Declaration 19/07/2019 David Branigan Disclosure of costs for drug research and development (R&D) and “alternative financing mechanisms” for new health products remain outstanding points to be resolved by countries in finalising a draft United Nations General Assembly political declaration on universal health coverage (UHC). A final draft of the declaration had been expected this week, but as of Friday […] Continue reading -> WHO is establishing technical advisory group and roster of experts on digital health 10/05/2019 Editorial team [WHO News Release] WHO is establishing a global multi-disciplinary technical group to advise us on issues related to digital health. Continue reading -> Drug Price Transparency: 10 Countries Back World Health Assembly Resolution 30/04/2019 Elaine Ruth Fletcher Ten countries, including five European Union (EU) member states, have now lined up in support of a landmark resolution to increase transparency of drug prices globally, which is expected to be a key focus of deliberations by WHO member states as they convene for the 72nd World Health Assembly (WHA), May 20-28 in Geneva. Image […] Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Drug Pricing Transparency To Be Discussed At World Trade Organization 17/10/2019 Grace Ren A request by South Africa to the World Trade Organization (WTO) TRIPS Council to “address the transparency of R&D costs and pricing of medicines and health technologies” is expected to be reviewed Friday, 18 October 2019 as the TRIPS Council meets this week for its third session this year. The TRIPS Council, the administrative body […] Continue reading -> Fueling An Unhealthy Future – Report Sheds New Light On Health Costs of Fossil Fuel Subsidies 26/09/2019 Elaine Ruth Fletcher NEW YORK CITY – Globally, governments are spending nearly $US 300 billion in price supports and other pre-tax subsidies for fossil fuels – which are costing national governments a whopping $US 2.7 trillion in health costs from air pollution-related mortality, disease and lost productivity—not to mention fueling climate change. As just one stunning example of […] Continue reading -> DR Congo Health Minister Resigns After President Takes Control Of Ebola Emergency 22/07/2019 Editorial team The Democratic Republic of the Congo’s Health Minister, Oly Iluga, resigned Monday, following his removal Saturday as the head of the country’s Ebola response – after the country’s President Felix Tshisekedi placed management of the crisis under direct presidential supervision. “As a result of your decision to place the response to the Ebola outbreak under […] Continue reading -> Drug R&D, Sexual & Reproductive Health Scrutinised In Draft UHC Declaration 19/07/2019 David Branigan Disclosure of costs for drug research and development (R&D) and “alternative financing mechanisms” for new health products remain outstanding points to be resolved by countries in finalising a draft United Nations General Assembly political declaration on universal health coverage (UHC). A final draft of the declaration had been expected this week, but as of Friday […] Continue reading -> WHO is establishing technical advisory group and roster of experts on digital health 10/05/2019 Editorial team [WHO News Release] WHO is establishing a global multi-disciplinary technical group to advise us on issues related to digital health. Continue reading -> Drug Price Transparency: 10 Countries Back World Health Assembly Resolution 30/04/2019 Elaine Ruth Fletcher Ten countries, including five European Union (EU) member states, have now lined up in support of a landmark resolution to increase transparency of drug prices globally, which is expected to be a key focus of deliberations by WHO member states as they convene for the 72nd World Health Assembly (WHA), May 20-28 in Geneva. Image […] Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Fueling An Unhealthy Future – Report Sheds New Light On Health Costs of Fossil Fuel Subsidies 26/09/2019 Elaine Ruth Fletcher NEW YORK CITY – Globally, governments are spending nearly $US 300 billion in price supports and other pre-tax subsidies for fossil fuels – which are costing national governments a whopping $US 2.7 trillion in health costs from air pollution-related mortality, disease and lost productivity—not to mention fueling climate change. As just one stunning example of […] Continue reading -> DR Congo Health Minister Resigns After President Takes Control Of Ebola Emergency 22/07/2019 Editorial team The Democratic Republic of the Congo’s Health Minister, Oly Iluga, resigned Monday, following his removal Saturday as the head of the country’s Ebola response – after the country’s President Felix Tshisekedi placed management of the crisis under direct presidential supervision. “As a result of your decision to place the response to the Ebola outbreak under […] Continue reading -> Drug R&D, Sexual & Reproductive Health Scrutinised In Draft UHC Declaration 19/07/2019 David Branigan Disclosure of costs for drug research and development (R&D) and “alternative financing mechanisms” for new health products remain outstanding points to be resolved by countries in finalising a draft United Nations General Assembly political declaration on universal health coverage (UHC). A final draft of the declaration had been expected this week, but as of Friday […] Continue reading -> WHO is establishing technical advisory group and roster of experts on digital health 10/05/2019 Editorial team [WHO News Release] WHO is establishing a global multi-disciplinary technical group to advise us on issues related to digital health. Continue reading -> Drug Price Transparency: 10 Countries Back World Health Assembly Resolution 30/04/2019 Elaine Ruth Fletcher Ten countries, including five European Union (EU) member states, have now lined up in support of a landmark resolution to increase transparency of drug prices globally, which is expected to be a key focus of deliberations by WHO member states as they convene for the 72nd World Health Assembly (WHA), May 20-28 in Geneva. Image […] Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
DR Congo Health Minister Resigns After President Takes Control Of Ebola Emergency 22/07/2019 Editorial team The Democratic Republic of the Congo’s Health Minister, Oly Iluga, resigned Monday, following his removal Saturday as the head of the country’s Ebola response – after the country’s President Felix Tshisekedi placed management of the crisis under direct presidential supervision. “As a result of your decision to place the response to the Ebola outbreak under […] Continue reading -> Drug R&D, Sexual & Reproductive Health Scrutinised In Draft UHC Declaration 19/07/2019 David Branigan Disclosure of costs for drug research and development (R&D) and “alternative financing mechanisms” for new health products remain outstanding points to be resolved by countries in finalising a draft United Nations General Assembly political declaration on universal health coverage (UHC). A final draft of the declaration had been expected this week, but as of Friday […] Continue reading -> WHO is establishing technical advisory group and roster of experts on digital health 10/05/2019 Editorial team [WHO News Release] WHO is establishing a global multi-disciplinary technical group to advise us on issues related to digital health. Continue reading -> Drug Price Transparency: 10 Countries Back World Health Assembly Resolution 30/04/2019 Elaine Ruth Fletcher Ten countries, including five European Union (EU) member states, have now lined up in support of a landmark resolution to increase transparency of drug prices globally, which is expected to be a key focus of deliberations by WHO member states as they convene for the 72nd World Health Assembly (WHA), May 20-28 in Geneva. Image […] Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Drug R&D, Sexual & Reproductive Health Scrutinised In Draft UHC Declaration 19/07/2019 David Branigan Disclosure of costs for drug research and development (R&D) and “alternative financing mechanisms” for new health products remain outstanding points to be resolved by countries in finalising a draft United Nations General Assembly political declaration on universal health coverage (UHC). A final draft of the declaration had been expected this week, but as of Friday […] Continue reading -> WHO is establishing technical advisory group and roster of experts on digital health 10/05/2019 Editorial team [WHO News Release] WHO is establishing a global multi-disciplinary technical group to advise us on issues related to digital health. Continue reading -> Drug Price Transparency: 10 Countries Back World Health Assembly Resolution 30/04/2019 Elaine Ruth Fletcher Ten countries, including five European Union (EU) member states, have now lined up in support of a landmark resolution to increase transparency of drug prices globally, which is expected to be a key focus of deliberations by WHO member states as they convene for the 72nd World Health Assembly (WHA), May 20-28 in Geneva. Image […] Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO is establishing technical advisory group and roster of experts on digital health 10/05/2019 Editorial team [WHO News Release] WHO is establishing a global multi-disciplinary technical group to advise us on issues related to digital health. Continue reading -> Drug Price Transparency: 10 Countries Back World Health Assembly Resolution 30/04/2019 Elaine Ruth Fletcher Ten countries, including five European Union (EU) member states, have now lined up in support of a landmark resolution to increase transparency of drug prices globally, which is expected to be a key focus of deliberations by WHO member states as they convene for the 72nd World Health Assembly (WHA), May 20-28 in Geneva. Image […] Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Drug Price Transparency: 10 Countries Back World Health Assembly Resolution 30/04/2019 Elaine Ruth Fletcher Ten countries, including five European Union (EU) member states, have now lined up in support of a landmark resolution to increase transparency of drug prices globally, which is expected to be a key focus of deliberations by WHO member states as they convene for the 72nd World Health Assembly (WHA), May 20-28 in Geneva. Image […] Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy